Amgen (4332) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4332 Analyst Ratings

Moderate Buy

7 Buy

10 Hold

1 Sell

Based on 18 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4332 Stock 12 Month Forecast

Average Price Target

HK$2,503.63

―

Based on 18 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is HK$2,503.63 with a high forecast of HK$3,023.26 and a low forecast of HK$2,113.95. The average price target represents a 1390807.42% change from the last price of HK$0.18.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1687":"HK$1,687","3024":"HK$3,024","2021.25":"HK$2,021.3","2355.5":"HK$2,355.5","2689.75":"HK$2,689.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3023.26123442,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$3.02K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2503.6333523292,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$2.50K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2113.95130016,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$2.11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1687,2021.25,2355.5,2689.75,3024],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1761,1858.0970180323077,1955.1940360646154,2052.2910540969233,2149.3880721292307,2246.4850901615387,2343.582108193846,2440.679126226154,2537.7761442584615,2634.8731622907694,2731.970180323077,2829.067198355385,2926.1642163876922,{"y":3023.26123442,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1761,1818.1256424868616,1875.2512849737232,1932.3769274605847,1989.502569947446,2046.6282124343077,2103.7538549211695,2160.879497408031,2218.005139894892,2275.1307823817538,2332.2564248686153,2389.382067355477,2446.5077098423385,{"y":2503.6333523292,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1761,1788.1501000123076,1815.3002000246154,1842.450300036923,1869.6004000492308,1896.7505000615383,1923.9006000738461,1951.0507000861537,1978.2008000984615,2005.350900110769,2032.501000123077,2059.6511001353847,2086.8012001476923,{"y":2113.95130016,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1688.903,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1705.868,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1705.868,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1705.868,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1724.001,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1724.001,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1724.001,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1742.403,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1742.403,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1742.403,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1761,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1761,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1761,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$3,023

Average Price TargetHK$2,504

Lowest Price TargetHK$2,114

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Veda Pharmyne

TR | OpenAI - 4o

HK$2,549.18→HK$2,821.19

Buy

1567229.09%

Upside

Reiterated

11/06/25

AI Generated ArticleAI Generated Article

Carter Gould

Cantor Fitzgerald

HK$2,370.42→HK$2,448.14

Hold

1359978.96%

Upside

Reiterated

11/06/25

Amgen price target raised to $315 from $305 at Cantor FitzgeraldAmgen price target raised to $315 from $305 at Cantor Fitzgerald

Tim Anderson

Bank of America Securities

HK$2,113.95

Sell

1174317.39%

Upside

Reiterated

11/05/25

Amgen Stock Overvaluation Concerns Amid Mixed Future Guidance and Pipeline Delays

Mohit Bansal

Wells Fargo

HK$2,176.13→HK$2,331.56

Hold

1295213.30%

Upside

Reiterated

11/05/25

Amgen price target raised to $300 from $280 at Wells FargoAmgen price target raised to $300 from $280 at Wells Fargo

Srikripa Devarakonda

Truist Financial

―

Hold

―

Reiterated

11/05/25

Truist Financial Sticks to Its Hold Rating for Amgen (AMGN)

Terence Flynn

Morgan Stanley

HK$2,588.04→HK$2,556.95

Hold

1420426.92%

Upside

Reiterated

11/05/25

Morgan Stanley Sticks to Its Hold Rating for Amgen (AMGN)

Luca Issi

RBC Capital

HK$2,564.72

Buy

1424744.63%

Upside

Reiterated

11/05/25

RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)

David Amsellem

Piper Sandler

HK$2,657.98

Buy

1476557.16%

Upside

Reiterated

11/05/25

Amgen (AMGN) Receives a Buy from Piper Sandler

Matt Phipps

William Blair

―

Buy

―

Reiterated

11/05/25

Amgen's Strong Q3 Performance and Promising Pipeline Justify Buy Rating

Yaron Werber

TD Cowen

HK$3,023.26

Buy

1679489.57%

Upside

Reiterated

11/04/25

Amgen's Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating

Evan Seigerman

BMO Capital

HK$2,603.58

Buy

1446333.18%

Upside

Reiterated

11/04/25

Amgen's Strong Financial Performance and Growth Potential Drive Buy Rating

Courtney Breen

Bernstein

HK$2,603.58

Buy

1446333.18%

Upside

Reiterated

10/27/25

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and UnitedHealth (NYSE: UNH)

Jay Olson

Oppenheimer

HK$2,953.31

Buy

1640630.18%

Upside

Reiterated

10/24/25

Oppenheimer Sticks to Their Buy Rating for Amgen (AMGN)

David Risinger

Leerink Partners

―

Hold

―

Reiterated

10/14/25

Analysts Conflicted on These Healthcare Names: Abbott Laboratories (NYSE: ABT), Amgen (NASDAQ: AMGN) and Pharvaris (NASDAQ: PHVS)

Geoff Meacham

Citi

HK$2,448.14

Hold

1359978.96%

Upside

Reiterated

10/10/25

Citi Keeps Their Hold Rating on Amgen (AMGN)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Veda Pharmyne

TR | OpenAI - 4o

HK$2,549.18→HK$2,821.19

Buy

1567229.09%

Upside

Reiterated

11/06/25

AI Generated ArticleAI Generated Article

Carter Gould

Cantor Fitzgerald

HK$2,370.42→HK$2,448.14

Hold

1359978.96%

Upside

Reiterated

11/06/25

Amgen price target raised to $315 from $305 at Cantor FitzgeraldAmgen price target raised to $315 from $305 at Cantor Fitzgerald

Tim Anderson

Bank of America Securities

HK$2,113.95

Sell

1174317.39%

Upside

Reiterated

11/05/25

Amgen Stock Overvaluation Concerns Amid Mixed Future Guidance and Pipeline Delays

Mohit Bansal

Wells Fargo

HK$2,176.13→HK$2,331.56

Hold

1295213.30%

Upside

Reiterated

11/05/25

Amgen price target raised to $300 from $280 at Wells FargoAmgen price target raised to $300 from $280 at Wells Fargo

Srikripa Devarakonda

Truist Financial

―

Hold

―

Reiterated

11/05/25

Truist Financial Sticks to Its Hold Rating for Amgen (AMGN)

Terence Flynn

Morgan Stanley

HK$2,588.04→HK$2,556.95

Hold

1420426.92%

Upside

Reiterated

11/05/25

Morgan Stanley Sticks to Its Hold Rating for Amgen (AMGN)

Luca Issi

RBC Capital

HK$2,564.72

Buy

1424744.63%

Upside

Reiterated

11/05/25

RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)

David Amsellem

Piper Sandler

HK$2,657.98

Buy

1476557.16%

Upside

Reiterated

11/05/25

Amgen (AMGN) Receives a Buy from Piper Sandler

Matt Phipps

William Blair

―

Buy

―

Reiterated

11/05/25

Amgen's Strong Q3 Performance and Promising Pipeline Justify Buy Rating

Yaron Werber

TD Cowen

HK$3,023.26

Buy

1679489.57%

Upside

Reiterated

11/04/25

Amgen's Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating

Evan Seigerman

BMO Capital

HK$2,603.58

Buy

1446333.18%

Upside

Reiterated

11/04/25

Amgen's Strong Financial Performance and Growth Potential Drive Buy Rating

Courtney Breen

Bernstein

HK$2,603.58

Buy

1446333.18%

Upside

Reiterated

10/27/25

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and UnitedHealth (NYSE: UNH)

Jay Olson

Oppenheimer

HK$2,953.31

Buy

1640630.18%

Upside

Reiterated

10/24/25

Oppenheimer Sticks to Their Buy Rating for Amgen (AMGN)

David Risinger

Leerink Partners

―

Hold

―

Reiterated

10/14/25

Analysts Conflicted on These Healthcare Names: Abbott Laboratories (NYSE: ABT), Amgen (NASDAQ: AMGN) and Pharvaris (NASDAQ: PHVS)

Geoff Meacham

Citi

HK$2,448.14

Hold

1359978.96%

Upside

Reiterated

10/10/25

Citi Keeps Their Hold Rating on Amgen (AMGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

1 Month

xxx

Success Rate

21/41 ratings generated profit

Average Return

+0.68%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 51.22% of your transactions generating a profit, with an average return of +0.68% per trade.

3 Months

xxx

Success Rate

16/26 ratings generated profit

Average Return

+2.97%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +2.97% per trade.

1 Year

Yaron WerberTD Cowen

Success Rate

30/41 ratings generated profit

Average Return

+11.01%

reiterated a buy rating 6 days ago

Copying Yaron Werber's trades and holding each position for 1 Year would result in 73.17% of your transactions generating a profit, with an average return of +11.01% per trade.

2 Years

xxx

Success Rate

27/34 ratings generated profit

Average Return

+12.19%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 79.41% of your transactions generating a profit, with an average return of +12.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4332 Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4332 has received 23 Buy Ratings, 15 Hold Ratings, and 2 Sell Ratings. 4332 average Analyst price target in the past 3 months is 2,503.63.

Each month's total comprises the sum of three months' worth of ratings.

4332 Financial Forecast

4332 Earnings Forecast

Next quarter’s earnings estimate for 4332 is HK$37.61 with a range of HK$34.52 to HK$44.63. The previous quarter’s EPS was HK$43.85. 4332 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 4332 has Preformed in-line its overall industry.

4332 Sales Forecast

Next quarter’s sales forecast for 4332 is HK$73.73B with a range of HK$71.60B to HK$76.77B. The previous quarter’s sales results were HK$74.52B. 4332 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 4332 has Preformed in-line its overall industry.

4332 Stock Forecast FAQ

What is HK:4332’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen’s 12-month average price target is 2,503.63.

What is HK:4332’s upside potential, based on the analysts’ average price target?

Amgen has 1390807.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Amgen a Buy, Sell or Hold?

Amgen has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 10 hold ratings and 1 sell ratings.

What is Amgen’s share price target?

The average share price target for Amgen is 2,503.63. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$3,023.26 ,and the lowest forecast is HK$2,113.95. The average share price target represents 1390807.42% Increase from the current price of HK$0.18.

What do analysts say about Amgen?

Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Amgen?

To buy shares of HK:4332, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Amgen (4332) Stock Forecast & Price Target

4332 Analyst Ratings

4332 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

4332 Analyst Recommendation Trends

4332 Financial Forecast

4332 Earnings Forecast

4332 Sales Forecast

4332 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts